China National Medicines Corporation Ltd.

Shanghai Stock Exchange 600511.SS

China National Medicines Corporation Ltd. Debt to Equity Ratio for the year ending December 31, 2023: 0.03

China National Medicines Corporation Ltd. Debt to Equity Ratio is 0.03 for the year ending December 31, 2023, a -17.19% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

China National Medicines Corporation Ltd. Debt to Equity Ratio for the year ending December 31, 2022 was 0.04, a -35.07% change year over year.
China National Medicines Corporation Ltd. Debt to Equity Ratio for the year ending December 31, 2021 was 0.06, a -20.36% change year over year.
China National Medicines Corporation Ltd. Debt to Equity Ratio for the year ending December 31, 2020 was 0.07, a 32.41% change year over year.
China National Medicines Corporation Ltd. Debt to Equity Ratio for the year ending December 31, 2019 was 0.05, a -52.34% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Shanghai Stock Exchange: 600511.SS

China National Medicines Corporation Ltd.

CEO	Mr. Guotao Tian
IPO Date	Nov. 27, 2002
Location	China
Headquarters	No. 12 A, Sanyuan West Alley
Employees	3,138
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

China National Medicines Corporation Ltd., together with its subsidiaries, distributes pharmaceutical products in China. The company also manufactures and sells new drugs and finished drugs; sells Chinese patent medicines and western medicines, and medical equipment; and offers warehousing and import and export agency services. It serves hospitals, retail pharmacies, and medical institutions. The company was founded in 1999 and is based in Beijing, China.

Key trends

Past 5 years